How FGFR isoform selectivity may shape the therapeutic window скачать в хорошем качестве

How FGFR isoform selectivity may shape the therapeutic window

Alexandra Drakaki, MD, PhD, University of California, Los Angeles, CA, discusses the isoform selectivity of the FGFR3 inhibitor, LY3866288, and its potential to avoid off-target toxicities associated with non-selective FGFR inhibitors, such as ocular, nail, and skin toxicity. Dr Drakaki highlights that the favorable safety profile of LY3866288, with mostly grade 1 and 2 toxicities, allows for combination strategies with other agents like enfortumab vedotin and pembrolizumab, as demonstrated by preliminary data from a cohort of patients with newly diagnosed metastatic urothelial cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.